Triple therapy shrinks bile duct tumors, may enable surgery

NCT ID NCT07030140

Recruiting now Disease control Sponsor: Jinbo Yue Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase II trial tests a combination of immunotherapy (tislelizumab), chemotherapy (gemcitabine plus cisplatin or oxaliplatin), and targeted radiation before possible surgery in 38 people with hilar cholangiocarcinoma that is borderline or not removable. The goal is to see if this approach can shrink tumors enough to allow complete surgical removal and improve overall survival. Participants who become eligible for surgery will have it; others will continue with more cycles of the drug combination.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: tislelizumab (an immunotherapy drug), gemcitabine, cisplatin or oxaliplatin, and stereotactic body radiotherapy
What this could lead to: If successful, this combination could shrink tumors enough to allow surgery in patients who otherwise cannot have it, potentially improving survival for this rare bile duct cancer.
What could go wrong: This is a small, early-phase trial with only 38 participants and no comparison group. The combination of immunotherapy, chemo, and radiation may cause significant side effects, and it is not yet known if it will improve long-term outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BILE DUCT CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

bile duct cancer bile duct neoplasm Biliary Tract Neoplasms cholangiocarcinoma hilar cholangiocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BILE DUCT CANCER CHOLANGIOCARCINOMA HILAR CHOLANGIOCARCINOMA

Contacts and locations

Locations

Shandong Cancer Hospital and Institute
RECRUITING

Jinan, Shandong, 250117, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.